A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2031-05-30
Target enrollment:
Participant gender:
Summary
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment
for Crohn's Disease in adults in China. Participants will receive an injection of Vedolizumab
300 mg at scheduled weeks 0, 2, and 6, and starting at week 14, every 8 weeks over 58 weeks
or starting at week 18, every 4 weeks over 54 weeks. There will be up to 20 study visits over
58 weeks to complete assessments.